Notably, because many of these metabolic disorders often present as co-morbidities in cancer patients, it is feasible that anti-CD36 therapy could also have the potential to simultaneously treat those disorders, adding even further therapeutic value for this emerging class of inhibitors. Here, CD36 is linked to cancer.